🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07211542
Recruiting Phase 2

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

NCT07211542 · tracked via the Priya Life Science China tracker
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 2
Started
2025-11-07
Last updated
2026-04-08

Condition(s) studied

Moderate-to-severe Atopic Dermatitis

Investigational drug(s) / intervention(s)

SHR-1905 InjectionSHR-1905 Injection Blank Preparation

SHR-1905 Injection: SHR-1905 injection.

SHR-1905 Injection Blank Preparation: SHR-1905 injection blank preparation.

Study summary

This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study. 2. At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female. 3. Have atopic dermatitis at screening. Exclusion Criteria: 1. Hypersensitivity to the study drug or any ingredient in the study drug. 2. Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD). 3. Has malignancy or has a history of malignancy. 4. Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial. 5. Females who are pregnant or lactating.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dermatology Hospital of Southern Medical University Guangzhou Guangdong Recruiting

More Guangdong Hengrui Pharmaceutical Co., Ltd trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07211542 on ClinicalTrials.gov ↗ ← All trials in China